- « Previous Releases | Next Releases »
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present a corporate summary and an update regarding the Company's clinical programs at the following investor conferences in New York:
Rodman & Renshaw Annual
Global Investment Conferenceon Monday, September 12, 2011at 2:00 p.m. Eastern time
Morgan Stanley Global Healthcare Conferenceon Tuesday, September 13, 2011at 2:10 p.m. Eastern Time
JMP Securities Healthcare Conferenceon Tuesday, September 27, 2011 8:30 a.m. Eastern Time
Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at www.BioCryst.com.
BioCryst Pharmaceuticalsdesigns, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the
SECand located at http://investor.shareholder.com/biocryst/sec.cfm.
BioCryst Pharmaceuticals Robert Bennett, 919-859-7910
News Provided by Acquire Media
- Rodman & Renshaw Annual